Saxenda: Underlying Mechanisms and Clinical Outcomes

NCT02944500 Phase 4 ACTIVE_NOT_RECRUITING

The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.

Details

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	Phase 4
Status	ACTIVE_NOT_RECRUITING
Enrolment	28
Start date	2016-11
Completion	2027-06

Conditions

• Obesity

Interventions

• liraglutide
• Placebo

Primary outcomes

• BOLD response to food cues — 5 weeks
  effect size of BOLD response to food cues in the brain

Countries

United States